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Abstract
Recently, the G protein-coupled receptor GPR30 has been
identiﬁed as a novel oestrogen receptor (ER). The
distribution of the receptor has been thus far mapped only
in the rat central nervous system. This study was undertaken
to map the distribution of GPR30 in the mouse brain and
rodent peripheral tissues. Immunohistochemistry using an
antibody against GPR30 revealed high levels of GPR30
immunoreactivity (ir) in the forebrain (e.g. cortex, hypo-
thalamus and hippocampus), speciﬁc nuclei of the midbrain
(e.g. the pontine nuclei and locus coeruleus) and the
trigeminal nuclei and cerebellum Purkinje layer of the
hindbrain in the adult mouse brain. In the rat and mouse
periphery, GPR30-ir was detected in the anterior, inter-
mediate and neural lobe of the pituitary, adrenal medulla,
renal pelvis and ovary. In situ hybridisation histochemistry
using GPR30 riboprobes, revealed intense hybridisation
signal for GPR30 in the paraventricular nucleus and
supraoptic nucleus (SON) of the hypothalamus, anterior
and intermediate lobe of the pituitary, adrenal medulla, renal
pelvis and ovary of both rat and mouse. Double
immunoﬂuorescence revealed GPR30 was present in both
oxytocin and vasopressin neurones of the paraventricular
nucleus and SON of the rat and mouse brain. The
distribution of GPR30 is distinct from the other traditional
ERs and offers an additional way in which oestrogen may
mediate its effects in numerous brain regions and endocrine
systems in the rodent.
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Introduction
Oestrogen (17-b-oestradiol or E2) affects a variety of
physiological processes including fertility, immune function,
cardiovascular homeostasis, mood, locomotion, neuroprotec-
tion and cognition (Watson & Gametchu 2001, McEwan
2002, de Ronde et al. 2003). E2 effects are typically mediated
through two structurally related oestrogen receptors, the
a and b (ERa and ERb) subtypes that function as ligand-
activated transcription factors. On activation ERs can either
bind directly to their target DNA sequences in the nucleus or
interact with other nuclear proteins to alter gene activation,
and this genomic action occurs slowly (hours–days).
However, it is well documented that E2 can also provoke
many fast ‘non-genomic’ effects e.g. activation of large
conductance calcium-activated potassium channels (Kca1.1;
Valverde et al. 1999), and these could be mediated by
extranuclear ERs or by non-classical membrane bound
receptors (Levin 2005).
GPR30,aG protein-coupled receptor (GPCR)speciﬁcally
binds E2 with high (nanomolar) afﬁnity and evokes rapid
effects (Revankar et al. 2005, Thomas et al. 2005), including
stimulating Ca
2C mobilisation from intracellular stores
directly or via epidermal growth factor receptor transactiva-
tion, c-fos expression, adenylyl cyclase and cAMP mediated
signalling and ERK-1/2 in a variety of cell types (Prossnitz
et al. 2008). Intriguingly, only a small fraction of total cellular
GPR30 appears to be expressed on the cell surface with most
of the receptor located intracellularly in the endoplasmic
reticulum (Revankar et al. 2007). GPR30 acts as an atypical
GPCR, in that, it is activated intracellularly by E2 which
readily diffuses across cell membranes (Revankar et al. 2007).
Recent studies in GPR30 knockout mice have indicated
that GPR30 mediates E2 stimulated insulin release in females,
reduces blood pressure and is involved in bone development,
but is not essential for reproduction (Ma ˚rtensson et al. 2009,
Otto et al. 2008). In addition, GPR30 is expressed in oxytocin
(OXT) neurones of the rat hypothalamic paraventricular
nucleus (PVH) and supraoptic nucleus (SON), implicating a
role for GPR30 in the fast, non-genomic actions of E2 on
OXT release (Wang et al. 1995, Revankar et al. 2005).
Whether or not GPR30 is expressed in vasopressin (AVP)
neurones remains unclear as one study found co-expression
(Brailoiu et al. 2007) while another did not (Sakamoto et al.
2007), boththese studies usedthe same antibody. A role for E2
in regulating OXTand/or AVP release is supported by studies
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increases circulating levels of OXT and AVP (Bossmar et al.
1995), and E2 rapidly stimulates intrahypothalamic and
peripheral OXT and possibly AVP release (Wang et al. 1995,
Burbach et al. 2001).
As GPR30 provides an alternative model for E2 signalling,
and possibly E2 stimulated release of OXT and AVP, the
present study was undertaken to clarify the distribution of
GPR30 in the rodent. As GPR30 provides an alternative
model for E2 signalling, and possibly E2 stimulated release of
OXTand AVP, the presentstudy was undertaken to clarify the
distribution of GPR30 in the rodent. We aimed to 1) map the
distribution of GPR30 in the mouse brain to determine
whether there are differences to that shown in the rat 2)
identify and highlight regions that express high levels of
GPR30 mRNA and protein in the rodent periphery, to
provide additional insights into the role of GPR30.
Materials and Methods
Animals
Adult male and female Sprague–Dawley rats, weighing
200–250 g (Harlan, Bicester, UK), and adult (10–12 week)
male and femalewild-type mice (25–30 g) from our AVP V1b
receptor knockout colony (Wersinger et al. 2002) were used
in this study. For each separate experiment (immunohisto-
chemistry, double immunoﬂuorescence or in situ hybrid-
isation histochemistry) three mice or rats of each gender were
used. Animals were housed under a constant temperature
(21G2 8C), light (lights on from 0700 to 1900 h) and
humidity (45–50%) regimens with access to food and water
ad libitum. Animal care, maintenance and surgery were
performed in accordance with the Animal Scientiﬁc
Procedures Act (1986) United Kingdom and the appropriate
University of Bristol ethical review process.
Immunohistochemistry
Animals were anaesthetised with sodium pentobarbital
(100 mg/kg i.p.) and intracardially perfused with 0.1M
PBS followed by 4% paraformaldehyde in 0.1 M PBS. Tissues
were post ﬁxed overnight in 20% sucrose and 4%
paraformaldehyde in 0.1 M PBS solution. Following over-
night ﬁxation, the tissues were rapidly frozen over liquid
nitrogen and stored at K80 8C until processed. In single
staining, rat and mouse peripheral cryostat sections (12 mm)
were cut and thaw-mounted onto Superfrost Plus slides, or
free-ﬂoating (40 mm) mouse brain sections were cut and
processed for GPR30-immunoreactivity (GPR30-ir). Tissues
were ﬁrst washed in 0.1 M PBS, endogenous peroxidase
activity was quenched with 3% H2O2 for 10 min, washed
(3!10 min with 0.1 M PBS), and then blocked with
10% normal goat serum (NGS) and 0.3% Triton-X 100
(T-X) in 0.1 M PBS for 15 min. After washing (3!10 min
with 0.1 M PBS), sections were incubated overnight in an
afﬁnity-puriﬁed rabbit antiserum against GPR30 diluted
(1: 1000–1:2000) in 1% NGS/0.3% T-X in 0.1 M PBS at
4 8C. The speciﬁcity of GPR30 antiserum has previously
been conﬁrmed (Revankar et al. 2005), and normal rabbit
IgG serum (Vector Laboratories, Peterborough, UK) was used
as a control at the same concentration as the antibody. After
washing (3!1 0 m i nw i t h0 .1M P B S ) , s e c t i o n s w e r e
incubated at room temperature in secondary biotinylated
afﬁnity puriﬁed goat anti-rabbit (1:500, Vector Laboratories),
in 1% NGS/0.3% T-X in 0.1 M PBS for 1 h, washed
(3!10 min with 0.1 M PBS) and incubated in horseradish
peroxidase streptavadin (1:500, Vector Laboratories) in 1%
NGS/0.3% T-X in 0.1 M PBS for a further hour. The
GPR30 signal was visualised with 3,30-diaminobenzidine in
peroxidase buffer (10 min at 1:10, Roche Diagnostics). Mouse
brain sections were mounted onto Superfrost Plus slides
with 0.5% gelatin solution, and along with the pre-mounted
peripheral sections were cover-slipped and viewed under a
light microscope (Leica DM IRB, Milton Keynes, UK).
For double immunoﬂuorescence staining, hypothalamic
free-ﬂoating sections (40 mm) were rinsed in 0.1 M PBS, and
then blocked with 10% NGS/0.3% T-X in 0.1 M PBS for
15 min. After washing (3!10 min in 0.1 M PBS), sections
were incubated overnight at 4 8C with rabbit antiserum
against GPR30 (diluted 1:1000) and guinea pig antiserum
against OXT or AVP (diluted 1:2000 (OXT), 1:500 (AVP);
Peninsula Laboratories, San Carlos, CA, USA). Sections were
washed and incubated for an hour at room temperature in
biotinylated goat anti-rabbit antibody (as above), and Alexa
Fluor 488 goat anti-guinea pig antibody (diluted 1:500,
Invitrogen) to detect OXT or AVP protein. Sections
were further washed and incubated for an hour in
streptavadin-conjugated Alexa Fluro 594 (diluted 1:500,
Vector Laboratories). Sections were mounted onto Superfrost
Plus slides, cover slipped with an antifade mounting medium
(Vectashield Hard Set, Vector Laboratories) and viewed under
a confocal laser scanning microscope (Leica TCS-NT
microscope housing a Leica DM IRBE inverted epiﬂuores-
cence with a two-line krypton/argon laser) and processed
with Adobe Photoshop CS3 extended computer software.
In situ hybridisation histochemistry
Coronal cryostat sections (12 mm) were cut, thaw mounted
onto polylysine-coated slides and stored at K80 8C until use.
The mouse GPR30 riboprobe was generated by PCR using
w20 ng mouse GPR30 cDNA (cloned from a mouse
AtT20 pituitary tumour cDNA library; SJL unpublished
data) as template. Primers (upstream: 50-GAGAGGATC-
CGGTCAGGGGCGCAGGC-30; downstream 50-AAA-
CAAGCTTTGTGAGAGGAGCATC-30) corresponding to
bp 1739–2344 of a mouse GPR30 mRNA (Genbank
Accession number NM_029771) were used to generate a
606 bp product. The primers contain the recognition
sequences for the restriction endonucleases HindIII and
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w150 ng rat genomic DNA (Promega no. G313A) as a
template. PCR primers (upstream: 50-GAGAGGATC-
CTCCTAGAGGAAAACGGA-30;d o w n s t r e a m5 0-AAA-
CAAGCTTTGTGAGAGGAGCATC-30) corresponding to
bp 15718722–15718072 of a rat GPR30 gene (Genbank
Accession number NM_133573) were used to generate a
651 bp product. The primers contain the recognition
sequences for the restriction endonucleases HindIII and
BamH1. Primer restriction endonuclease sites allowed
subcloning into the RNA generating vector pGEM4Z
(Promega), and sense and antisense probes were generated
using T7 and SP6 polymerases (mouse and rat antisense:
linearised with BamHI and generated with T7 polymerase;
sense: linearised with HindIII and generated with SP6
polymerase) with
35S-UTP and the MAXIscript in vitro
transcription kit (Ambion, Austin, TX, USA). The integrity
of the probes was veriﬁed by DNA sequencing. All in situ
hybridisation experiments were performed as described
in detail (http://intramural.nimh.nih.gov/lcmr/snge/Proto-
cols/ISHH/ISHH.html).
Hybridised sections were exposed to ﬁlm (Amersham
Hyperﬁlm MP) for 8 weeks, or emulsion dipped (Ilford K5)
for 24 weeks and then counterstained with toluidine blue.
Results
Distribution of GPR30-ir in the adult mouse brain
The data presented here are semi-quantitative assessments
based on subjective judgement of three independent
observers. No apparent gender differences were observed in
the distribution of GPR30 in the adult mouse brain. In most
brain regions, GPR30-ir was expressed in cell bodies and
ﬁbres; in some regions mostly cell bodies (e.g. paraventricular
nucleus of the thalamus, hypothalamic ventromedial nucleus
(VMH)) or ﬁbres (e.g. lateral mammillary nucleus) expressed
GPR30-ir (see Table 1 and Figs 1–3).
In the forebrain GPR30-ir expression was high in the
cingulate, motor (Fig. 1A) and somatosensory regions of the
isocortex, piriform cortex (Fig. 1B), entorhinal cortex, the
dentate gyrus hilus (Fig. 2A), and subiculum of the dorsal
hippocampus formation and the zona incerta (Fig. 2B).
Moderate to high expression was identiﬁed in the mitral layer
of the olfactory bulb, dorsal endopiriform nucleus, CA1–3 of
the ventral hippocampal formation, the medial habenular
nucleus of the thalamus, anteroventral periventricular nucleus
and the medial preoptic nucleus. The retrosplenial granular
region of the isocortex, the lateral nucleus of the septal
complex, the nucleus of the horizontal limb of the diagonal
band of broca, the olfactory tubercle, the anterior amygdaloid
area of the amygdala and the paraventricular nucleus of the
thalamus (Fig. 1D), all demonstrated moderate expression of
GPR30. Low to moderate staining was noted in the granular
insular, perirhinal and retrosplenial agranular regions of the
isocortex, medial nucleus of the septal complex and the CA2
of the dorsal hippocampal formation. Expression of GPR30
was low in many areas including the glomerular layer of the
olfactory bulb, islands of Calleja, claustrum, caudate putamen
of the striatum, shell of the accumbens nucleus, subfornical
organ, CA1 and CA3 of the dorsal hippocampal formation,
bed nucleus of the stria terminalis, and amygdalohippocampal
nucleus and medial nucleus of the amygdala. The data are
summarised in Table 1.
In the hypothalamus intense GPR30 expression was found
in the arcuate nucleus, PVH (Fig. 1E), periventricular
hypothalamic nucleus, SON (Fig. 1C), dorsomedial, central
and ventrolateral divisions of the VMH with moderate to
high expression in the suprachiasmatic nucleus and lateral
mammillary nucleus. GPR30-ir was low in the dorsal–medial
nucleus, medial mammillary nucleus and ventral tuberomam-
millary nucleus and GPR30 expression is sparse in the lateral
hypothalamic area, posterior hypothalamic nucleus, subtha-
lamic nucleus and supramammillary nucleus.
In the midbrain and pons, distinct GPR30-ir could be seen
in the pontine nuclei, anterior tegmental nucleus, medio-
ventral periolivary nucleus and superior paraolivary nucleus
of the superior olive and the locus coeruleus (Fig. 3B).
A moderate to high expression was noted in the inter-
peduncular nucleus, compact region of the substantia nigra
(Fig. 2E) and the reticulotegmental nucleus of pons. The
dorsal medial periaqueductal grey, inferior colliculus, caudal
linear raphe nuclei, oral pontine reticular nucleus, the rostal,
dorsal, caudal periolivary regions and the lateral superior
olivary nucleus of the superior olive, nucleus of trapezoid
body, lateral nucleus of the parabrachial region and the medial
vestibular nucleus all express moderate levels of GPR30. On
the other hand, low levels were found in areas such as the
lateral and reticular regions of the substantia nigra, superior
colliculus, dorsal raphe and the lateral vestibular nucleus.
In the hindbrain, high expression of GPR30 was found
in the oral and dorsomedial region of the spinal trigeminal
nucleus (Fig. 3C and D). GPR30-ir was also high in the
Purkinje cells of the cerebellum. Moderate expression was
seen in the facial motor nucleus, principal nucleus of the
inferior olive and the dorsal motor nucleus of vagus with
low to moderate expression in the middle cerebellar
peduncle, nucleus ambiguous and nucleus of the solitary
tract. Low to moderate staining was also found in the
internal granule layer and molecular layers of the
cerebellum. Low expression was detected in other regions
including the posterodorsal tegmental nucleus, supratri-
geminal, parapyramidal, intermediate reticular, gigantocel-
lular, lateral reticular and the rosteroventrolateral reticular
nuclei and the area postrema.
GPR30 co-localises with OXTand AVP neurones
The results for this part of the study were obtained from
three male and three female rat and mouse brains, double
labelled with antibodies to GPR30 and either OXTor AVP.
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(ir) in the adult brain, determined using three males and three
females. Data presented here are of semi-quantitative assessments
and the intensity of staining is based on the subjective judgement of
three observers. No apparent gender differences were detected
GPR30
Brain region
Forebrain
Olfactory bulb
Glomerular layer C/c
Mitral layer CC/CCC/c
External plexiform layer K
Granule layer K
Islands of Calleja C/c
Cortex
Allocortex
Piriform CCC/c
Dorsal endopiriform nucleus CC/CCC/f
Isocortex
Agranular insular K
Cingulate CCC/c
Dorsal peduncular K/C/c
Granular insular C/CC/c
Infra-limbic K/C/c
Prelimbic K/C/c
Motor CCC/c
Somatosensory CCC/c
Perirhinal C/CC/c
Retrosplenial agranular C/CC/c
Retrosplenial granular CC/c
Visual K/C/c
Dorsal tenia tecta K
Claustrum C/f
Striatum
Caudate putamen C/f
Globus pallidus K
Septal complex
Lateral nucleus CC/c
Medial nucleus C/CC
Septohippocampal nucleus K
Diagonal band of broca
Horizontal limb diagonal band CC
Vertical limb diagonal band C/c
Accumbens nucleus
Shell C/c
Core K/C/c
Ventral pallidum K/C/c
Subfornical organ C/c
Hippocampal formation – dorsal
CA1 C
CA2 C/CC
CA3 C
Dentate gyrus hilus CCC
Subiculum CCC/c
Hippocampal formation – ventral
CA1–CA3 CC/CCC
Entorhinal cortex CCC/c
Internal capsule K
Bed nucleus of the stria terminalis C
Interstitial nucleus post limb anterior
commisure
C
Olfactory tubercle CC/c
Substantia innominata C
(continued)
Table 1 Continued
GPR30
Amygdala
Anterior amygdaloid area CC
Amygdalohippocampal nucleus C/c
Basolateral nucleus K
Basomedial nucleus K
Cortical amygdaloid nucleus K
Central nucleus K
Medial nucleus C
Thalamus
Anterodorsal nucleus K
Mediodorsal nucleus K
Central medial nucleus K/C/c
Paraventricular nucleus CC/c
Rhomboid nucleus K
Medial habenular nucleus CC/CCC/c
Precommisural nucleus K
Pretectal nucleus K
Lateral posterior thalamic nucleus K
Ventral medial thalamic nucleus K
Zona incerta CCC
Subincertal nucleus C/c
Preoptic area
Anteroventral periventricular nucleus CC/CCC/c
Lateral preoptic nucleus C/c
Medial preoptic nucleus CC/CCC/c
Magnocellular preoptic area K
Hypothalamus
Anterior commissural nucleus K
Anterior hypothalamic nucleus K
Arcuate nucleus CCC
Dorsomedial nucleus K
Lateral hypothalamic area K/C/c
Paraventricular hypothalamic nucleus CCC
Periventricular hypothalamic nucleus CCC/c
Posterior hypothalamic nucleus K/C
Subthalamic nucleus K/C
Suprachiasmatic nucleus CC/CCC
Supraoptic nucleus CCC
Ventromedial hypothalamic nucleus
Dorsomedial CCC/c
Cental CCC/c
Ventrolateral CCC/c
Lateral mammillary nucleus CC/CCC
Medial mammillary nucleus C
Supramammillary nucleus K/C
Ventral tuberomammillary nucleus C
Midbrain/pons
Deep mesencephalic nucleus K
Edinger–Westphal nucleus K/C
Interfascicular nucleus K/C
Interpeduncular nucleus CC/CCC
Suprageniculate thalamic nucleus K/C
Substantia nigra (caudal)
Compact CC/CCC
Lateral C/c
Reticular C/c
Ventral tegmental area K
Nucleus brachium inferior colliculus K/C
Parabrachial pigmented nucleus K/C/c
Periaqueductal gray
Dorsal medial CC/c
Superior colliculus C
(continued)
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merged with the corresponding immunoﬂuorescence pic-
tures of OXTor AVP. Neurones containing both GPR30-ir
(red) and OXT-ir or AVP-ir (green) appeared yellow
(merged) and were counted, and a co-expression percentage
was calculated against the total number of OXT-ir or AVP-ir
neurones.
In the rat PVH, GPR30-ir is prominent in the
magnocellular PVH with low-level labelling in the parvocel-
lular PVH (Fig. 4). Dual labelling of hypothalamic sections
revealed that GPR30-ir was present in both OXT and AVP
magnocellular neurones and 40–60% of OXT neurones and
50–70% co-expressed GPR30-ir in the PVH and SON (see
Table 2 and Figs 4 and 5). In the PVH and SON of the mouse
both OXT and AVP neurones were positive for GPR30-ir,
with 60–80% of OXT and AVP neurones expressing the
receptor (Figs 4 and 5). Co-localisation of GPR30-ir with
OXTand AVP was also observed in ﬁbres in the internal zone
of the median eminence of both species.
Table 1 Continued
GPR30
Inferior colliculus CC
Raphe nuclei
Rostal linear K/C
Caudal linear CC
Medial/paramedian K/C
Dorsal raphe C
Pontine nuclei CCC/c
Pontine reticular nucleus
Oral CC/c
Caudal K
Intercollicular nucleus K
Lateral lemniscus K/C
Parabigeminal nucleus K
Dorsal tegmental nucleus C/CC
Pedunculopontine tegemental nucleus K
Reticulotegmental nucleus pons CC/CCC
Anterior tegmental nucleus CCC
Superior olive
Medioventral periolivary nucleus CCC/c
Rostral periolivary region CC
Dorsal periolivary region CC/c
Superior paraolivary nucleus CCC/c
Caudal periolivary nucleus CC
Lateral superior olivary nucleus CC
Nucleus of trapezoid body CC
Locus coeruleus CCC/c
Subcoeruleus nucleus K/C
Parabrachial
Medial nucleus K
Lateral nucleus CC
Medial vestibular nucleus CC
Lateral vestibular nucleus C
Hindbrain/cerebellum
Raphe nuclei
Magnus K/C
Pallidus K/C
Obscurus K/C
Middle cerebellar peduncle C/CC/f
Posterodorsal tegmental nucleus C
Supratrigeminal nucleus C
Facial motor nucleus CC
Parapyramidal nucleus C
Intermediate reticular nucleus C
Gigantocellular reticular nucleus C
Lateral reticular nucleus C
Paragigantocelluar reticular nucleus K/C
Rostoventrolateral reticular nucleus C
Nucleus ambiguus C/CC/c
Prepositus nucleus CC
Nucleus solitary tract C/CC
Area postrema C
Inferior olive, principal nucleus CC
Dorsal motor nucleus of vagus CC
Trigeminal nucleus, sensory CCC/c
Spinal trigeminal nucleus CCC/c
Spinal trigeminal nucleus, oral CCC/c
Cerebellum
Molecular layer K/C
Purkinje cell layer CCC/c
Internal granule layer C/CC
Intensity of label: CCC, intense; CC, moderate; C, low; K, absent; (c),
cells;(f),ﬁbres;allotherregionscontainbothimmunoreactivecellsandﬁbres.
Figure 1 Immunoreactivity for GPR30 in the adult male or female
mouse brain: labelled cells in the supplementary motor cortex (A),
piriform cortex (B), labelled cells and ﬁbres in the SON (C), with
moderate labelling of cells in the paraventricular nucleus of the
thalamus (D), labelled cells and ﬁbres in the PVH (E) with an
absence of labelling in the PVH with a section incubated with IgG
in place of GPR30 antiserum (F). M2, supplementary motor cortex;
PIR, piriform cortex; SON, supraoptic nucleus of the hypothalamus;
PVT, paraventricular nucleus of the thalamus; PVH, paraventricular
nucleus of the hypothalamus; OC, optic chiasm; 3V, third ventricle.
Scale bars, 100 mm in (A–B and E–F); 50 mm in (C–D). A lower
magniﬁcation of the PVT is inserted in (D) (Scale barZ100 mm).
D3V, dorsal third ventricle.
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In the anterior lobe of the pituitary gland, w50% of cellswere
intensely stained for GPR30-ir. The majority of cells in the
pituitary intermediate lobe stained positively and there was
prominent staining of ﬁbres in the neural lobe (Fig. 6A). The
adrenal medulla displayed strong GPR30-ir; occasional
GPR30-ir cells were also observed in the zona glomerulosa
of the cortex. In the kidney, GPR30-ir was present in the
smooth-muscle cells of the pelvic region and to a lesser extent
the medulla, with only a few positive cells in the cortex
(Fig. 6B). In the ovary, dense staining was found within the
granulosa cellswith moderate to low staining in the theca cells
(Fig. 6C). Staining was absent in corporalutea. Therewereno
species or gender differences observed in the peripheral
distribution of GPR30 protein expression in the three male
and three female rats and mice analysed.
Distribution of GPR30 mRNA
We determined the expression of GPR30 mRNA in tissues
that displayed abundant GPR30-ir in tissues from three male
and three female rats and mice. In the rat central nervous
system, a hybridisation signal for GPR30 was detected in the
PVH and SON particularly in the magnocellular region ofthe
PVH (Fig. 7A and C). In the pituitary gland, the intermediate
lobe was intensely labelled (Fig. 7D–F) and scattered cells
exhibited a moderate signal in the anterior lobe. The neural
lobe was unlabelled. In the adrenal glands, high levels of
GPR30 mRNAwere present in the adrenal medulla and cells
within the zona glomerulosa of the adrenal cortex (Fig. 8A
and B). In the kidney, intense labelling was present in the
smooth muscle of the renal pelvis, and to a lesser extent in the
medulla, with some sparse labelling in the cortex (Fig. 8C).
A few developing follicles of the rat ovary exhibited a
hybridisation signal (data not shown). A similardistribution of
GPR30 transcripts was observed in mouse tissues- the SON,
the adrenal medulla and pituitary intermediate lobe expressed
the highest amount of GPR30 mRNA compared with
kidney, ovary and PVH based on signal intensities observed
for the same ﬁlm exposures. Figure 8E shows GPR30 mRNA
expression in developing follicles of the mouse ovary, with
silver grains accumulated mainly in the granulosa and theca
cells. No signal was detected in the corpora lutea. Rat and
mouse sections hybridised with sense GPR30 riboprobes as
controls showed only background level of labelling (Figs 7B
and 8D and E).
Figure2 Immunoreactivity for GPR30 in the adult male or female
mouse brain: labelled cells and ﬁbres in the dentate gyrus of the
hippocampus (A), zona incerta (B), arcuate nucleus and cell
bodies of the ventromedial hypothalamic nucleus (C), GPR30-ir
in cells and ﬁbres of the lateral mamillary nucleus of the
hypothalamus (D), labelled cells and ﬁbres of the pars compacta
of the substantia nigra (E) and labelled cells of the pontine
nuclei (F). DG, dentate gyrus of the hippocampus; ZI, zona
incerta; Arc, arcuate nucleus of the hypothalamus; VMH,
ventromedial hypothalamic nucleus; LM, lateral mamillary
nucleus of the hypothalamus; SNC, pars compacta of the
substantia nigra; Pn, pontine nuclei; 3V, third ventricle. Scale
bars, 100 mm in (A–D); 50 mm in (E–F). In E and F, lower
magniﬁcations of the SNC and Pn respectively, are shown
(scale barsZ200 mm).
Figure 3 Immunoreactivity for GPR30 in the adult male or
female mouse brain: labelled cells of the Purkinje cell layer of
the cerbellum (A), locus coeruleus (B) and sensory trigeminal
nucleus (C) enlarged in (D). pcL, Purkinje cell layer of the
cerbellum; lc, locus coeruleus; PrS, sensory trigeminal
nucleus; 4V, fourth ventricle. Scale bars, 100 mm in (A–C);
50 mm in (D). In (C), a lower magniﬁcation of Pr5 is shown
(scale barZ200 mm).
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GPR30 was originally cloned by us as an orphan GPCR over
10 years ago (Owman et al. 1996) and subsequently identiﬁed
as an ER in a number of laboratories (Filardo et al. 2000,
2002, Revankar et al. 2005, Thomas et al. 2005). Unlike many
GPCRs, GPR30 appears to be predominantly expressed and
functions intracellularly at least in vitro (Revankar et al. 2007).
It has been reported that GPR30 is also found on the plasma
membrane where it appears to be functionally relevant
(Filardo et al. 2007). Further studies on GPR30 internal-
isation and trafﬁcking are required to address this issue. The
suggestion that a GPCR is primarily localised intracellulary is
not without precedent- e.g. the proportion of human GnRH
receptors at the cell surface is extremely low (!1%; Finch
et al. 2008) and depends upon the cellular context (the
proportion of human GnRH receptors at the cell surface is
ﬁve times greater in a gonadotroph cell line (LbT2) than
MCF7 breast cancer cells (Finch et al. 2008)). Homologues of
the human, rat and mouse GPR30 are present in many species
including rhesus monkey, chimpanzee, dog, chicken and
zebraﬁsh (see NCBI or Ensembl databases at www.ncbi.nlm.
nih.govor www.ensembl.org respectively). The GPR30 gene
is widely distributed in human and rat tissues as shown by
northern blot and immunohistochemical analyses (Owman
et al. 1996, Bonini et al. 1997, Carmeci et al. 1997, Feng &
Gregor 1997, Kvingedal & Smeland 1997, Brailoiu et al.
2007) and see EST proﬁle Hs.20961 in NCBI Entrez
Figure 4 Double label immunoﬂuorescence for GPR30 and AVP in the adult rat PVH (A–C),
SON (D–F) and median eminence (G–I), and GPR30 and OXTin the adult mouse PVH (J, K
and L). Immunoreactivities against GPR30 (A, D, G and J; red) and AVP (B, E and H; green) or
OXT (K; green) were merged in each right panel (C, F, I and L; overlap yellow) respectively.
G–L were captured using a laser confocal microscope. 3V, third ventricle; OC, optic chiasm.
Scale bars, 100 mm in (A–F); 80 mm in (G–L).
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present study using immunohistochemistry and in situ
hybridisation histochemistry to obtain the cellular context
of GPR30 expression in mouse brain and peripheral tissues.
Distribution of GPR30-ir in the adult mouse brain
The present study provides the ﬁrst full comprehensive
characterisation of GPR30 distribution in the mouse central
nervous system. Previously, the distribution of GPR30 has
been illustrated in the rat brain using the same GPR30
antiserum as described here (Brailoiu et al.2 0 0 7 ). In
agreement with our ﬁndings in mice, there are no apparent
gender differences in GPR30 expression in the rat and this
appears common to all E2 receptors (Laﬂamme et al. 1998).
Brailoiu et al. (2007) found predominant GPR30 expression
in the hypothalamic PVH and SON, hippocampal formation,
substantia nigra in the rat brain and this correlates well with
our observations in the mouse brain. However, GPR30 is also
highly expressed in the nucleus ambiguous where only low to
moderate expression is found in the equivalent area in the
mouse brain, suggesting some species differences. A compari-
son of GPR30 mRNA versus protein localisation in both rat
and mouse brains may reveal whether receptor transcription
and translation coincide or whether there are mismatches.
Comparison of ER distribution in the adult mouse brain
There appears to be only a few brain regions that express high
levels of GPR30 and high amounts of either ERa or ERb and
even fewer regions that express all three receptors (see
Table 3) to a high degree. For example, GPR30 is most
abundant in the hypothalamus of the mouse, particularly the
arcuate nucleus, PVH, periventricular nucleus, SON and the
dorsomedial, central and ventrolateral regions of the VMH.
Of these nuclei, ERa is highly expressed in the arcuate
nucleus and in the ventrolateral portion of the VMH, and in
rats priming the VMH with E2 over days promotes lordosis,
seemingly through ERa (Pfaff & Sakuma 1978).In the rat and
mouse, hypothalamus ERb is the predominant ER isoform
found in the PVH (Mitra et al. 2003, Merchenthaler et al.
2004). Interestingly, E2 has been shown to activate the
(MAPK) ERK 1/2 pathway in the PVH and SON of the
mouse (A ´braha ´m et al. 2004). In the PVH, this is potentially
mediated via either ERb and/or GPR30, and presumably
GPR30 in the SON.
In the forebrain, GPR30 is also highly expressed in the
cingulate, motor and somatosensory regions of the isocortex,
piriform cortex, the hippocampal dentate gyrus hilus,
subiculum and entorhinal cortex, and the zona incerta
where ERa and ERb expression is either low or absent.
Interestingly, E2 has been shown to induce c-fos protein
expression in some brain regions (e.g. cingulate cortex) of
double ERab knockout mice. As GPR30 is abundant in this
region, GPR30 or another E2-binding protein may mediate
the effects of E2 (Dominguez-Salazar et al. 2006). On the
other hand, ERa and b are both highly expressed in the bed
nucleus of the stria terminalis and the medial nucleus of the
amygdala, where only minimal amounts of GPR30 can be
detected.
In the midbrain and pons, high expression of GPR30 is
found in the pontine nuclei, anterior tegmental nucleus, the
medioventral periolivary nucleus and superior paraolivary
nucleus of the superior olive, and the locus coeruleus. Of
these, only the locus coeruleus contains high levels of the
ERs. Interestingly in the mouse, noradrenaline neurones of
the locus coeruleus have been shown to be responsive to E2
stimulation with an upregulation in tyrosine hydroxylase
transcription in females, and attenuation of transcription in
males (Thanky et al. 2002). This gender difference could be
indicative of the varying roles of all the three ERs that are
highly expressed in this brain region.
GPR30 co-localises with OXTand AVP neurones
The present study also aimed to clarify the inconsistencies in
the literature regarding the distribution of GPR30 in
hypothalamic magnocellular neurones. Our ﬁndings conﬁrm
that in the rat and mouse hypothalamus both OXTand AVP
neurones express GPR30. This is in agreement with
observations of Brailoiu et al. who found co-localisation of
GPR30 with OXTand AVP in magnocellular neurones of the
rat PVH and SON, but contrast with those of another study
that detected GPR30 only in OXT neurones of the PVH and
SON of the same species (Brailoiu et al. 2007, Sakamoto et al.
2007). The reasons for these discrepancies are not readily
apparent, especially since all three studies used the same
antiserum directed against the GPR30 protein (Revankar
et al. 2005). To conﬁrm the speciﬁcity of GPR30-ir in the
present study we substituted normal rabbit IgG serum for
primary antibody at the same concentration, and did not
observe any staining (Fig. 1F).
E2 mediates the release of OXT and AVP in vivo and
in vitro. It rapidly stimulates intrahypothalamic OXTand AVP
release and rapid peripheral OXT and possibly AVP release
Table 2 Summary of GPR30 co-localisation with oxytocin and
vasopressin neurones in the rodent paraventricular (PVN) and
supraoptic nuclei (SON) of the hypothalamus
OXT
Co-localised
GPR30 and
OXT (%) AVP
Co-localised
GPR30 and
AVP (%)
Rat PVN 223 50.6G10.4 160 59.1G6.3
Rat SON 148 54.6G8.3 181 62.1G7.4
Mouse PVN 191 70G6.5 152 70.6G8.2
Mouse SON 219 74.6G8.9 131 64.2G7.8
Values represent the total number of OXT and AVP neurones counted in
sections of PVN and SON obtained from three male and three female
animals, and the average percentage (GS.D.) that also express GPR30-ir.
There was no apparent difference in the number of co-expressing neurones
between the anterior, middle and posterior PVN in either rat or mouse.
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inhibits the release of both peptides from hypothalamo-
neurohypophysial explants stimulated hyperosmotically via a
non-genomic action (Swenson & Sladek 1997) and rapidly
alters the electrophysiological properties of OXT cells in the
SON of lactating or morphine-dependent rats (Israel &
Poulain 2000, Brown et al. 2008). OXTand AVP neurones of
the rat PVH and SON, express ERb (Hrabovszky et al. 2004).
It is well established that ERs can stimulate second messenger
pathways, perhaps via receptors tethered to the plasma
membrane, as well as alter gene activation in the nucleus,
suggesting that the rapid E2 effects on OXT/AVP synthesis
and release could be modulated through extranuclear ERb at
the level of the hypothalamus (Razandi et al. 2003, 2004,
Levin 2005). Alternatively, E2 could regulate AVP and OXT
neuronal activity by indirectly activating ERa/b-expressing
neurones that project to the PVH and SON (Shughrue et al.
1997, Hrabovszky et al. 2004, Sladek & Somponpun 2004).
The relative contribution of GPR30 in E2 effects on
hypothalamo-neurohypophysial activity is not known.
However, ERb immunoreactivity is absent from the neural
lobe suggesting that E2 does not directly mediate peripheral
release of OXT and AVP at the level of the pituitary via this
receptor (Pelletier et al. 2000). Interestingly in the present
Figure 5 Double label immunoﬂuorescence for GPR30, OXTand AVP in the adult rat SON
and mouse PVH. Immunoreactivities against GPR30 (A, D and G; red) and OXT (B; green) or
AVP (E and H; green) were merged in each right panel (C, F and I; overlap yellow)
respectively. Arrows indicate OXT or AVP immunoreactive cell bodies that also contain
GPR30-immunoreactivity. Note that some GPR30-ir cells (arrowhead) do not express OXT-ir
or AVP-ir. In addition to staining of cell bodies, there also appears to be co-expression of
GPR30-ir and OXT-ir in processes (that may be axons or dendrites), suggesting that the
receptor may be axo-dendritically transported, as has been well-established for the
neuropeptide (see open arrows). The presence of possible intracellular staining of GPR30
within OXT and AVP neurones which is consistent with the predominantly cytoplasmic
distribution of GPR30 that has been observed in various cell types in vitro (see discussion for
details). Pictures captured at the same low magniﬁcation using a laser confocal microscope.
Scale bars, 10 mm in (A–I).
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indicating that E2 could modulate the peripheral release of
OXTand AVP through GPR30 signalling. As wewere unable
to detect GPR30 mRNA in the neural lobe, it can be
assumed that the receptor had been transported, presumably
from the magnocellular neurones in the PVH and SON, aswe
also observed co-localisation of GPR30 with OXTand AVP
ﬁbres in the internal zone of the median eminence. It is
possible that GPR30 regulates OXT and AVP synthesis in
PVH and SON magnocellular cell bodies, and/or modulates
OXT and AVP release from PVH and SON magnocellular
neurone dendrites or from ﬁbres that terminate in the
posterior pituitary. Our studies also suggest that GPR30 could
mediate E2 effects on the hypothalamic–pituitary adrenal axis
by modulating the release of OXT, AVPor perhaps CRF into
portal bloodfromneurones originating from the parvocellular
region of the PVH.
Peripheral distribution of GPR30
The present study demonstrates high expression of GPR30
mRNA and protein in the pituitary gland, adrenal medulla,
renal pelvis and ovary of the rat and mouse. There is a strong
correlation between the tissue distribution of both GPR30
mRNA and protein, apart from that in the neural lobe of the
pituitary.
While GPR30 protein is expressed in all three lobes of the
pituitary with the highest mRNA expression was observed in
the intermediate lobe. ERa and ERb are also expressed in the
anterior and intermediate lobes, but are absent from the
posterior lobe of the pituitary (Mitchner et al. 1998, Pelletier
et al. 2000, Gonza ´lez et al. 2008). It is well established that the
anterior pituitary is a target tissue for E2,r e g u l a t i n g
gonadotrophin and prolactin (PRL) secretion from gonado-
trophs and lactrotrophs, and this response can be rapid, with
E2 increasing excitability in PRL-secreting pituitary cell lines
within minutes (Dufy et al. 1979). High expression of GPR30
mRNA and protein in the intermediate lobe and the presence
of the traditional E2 receptors suggests a possible role for E2 in
pro-opiomelanocortin synthesis and a-melanocyte stimulat-
ing hormone (a-MSH) and ACTH-like peptide release.
A previous study has shown that E2 stimulates the release of
a-MSH from the intermediate lobe which in turn appears to
exert a rapid stimulatoryeffect on PRL secretion (Ellerkmann
et al. 1992).
Figure 6 Immunohistochemical analysis of GPR30 in rodent
peripheral tissues. (A) GPR30-ir in rat pituitary is prominent in the
nerve terminals of the neural (posterior) lobe (NL) and is present in
most melanotrophs of the intermediate lobe (IL) (e.g. indicated by
arrows). GPR30-ir is also found in scattered (w50%) cells in the
anterior pituitary (AP) lobe. Whether these represent endocrine
cells (e.g. prolactotrophs and corticotrophs) was not determined.
(B) High levels of GPR30-ir are present in the rat renal pelvis (RP),
an extension of the ureter, with projections into the renal inner
medulla (IM). (C) In the rat ovary, GPR30-ir is found mainly in the
granulosa cells (G), with some staining of theca cells (T) of the
developing follicle. Scale bars, 400 mm in (B); 50 mm in (A and C).
Figure 7 In situ hybridisation of GPR30 mRNA in the rodent PVH,
SON and pituitary gland: reversed image of emulsion dipped
section of the rat PVH the GPR30 hybridisation grains appear white
in the picture (A) (but black on the actual slide); the corresponding
sense slide is absent of black GPR30 hybridisation grains (B); low-
magniﬁcation photographs of ﬁlm autoradiographic images of a
slide mounted hypothalamic section hybridised with a GPR30
probe, with signal in the PVH and SON of the rat brain (C), and
pituitary sections hybridised with a GPR30 probe in rat (D) and
mouse (E) with intense signal in both intermediate lobes; emulsion
dipped section of the mouse pituitary, hybridisation signal for
GPR30 mRNA appears as black grains (E). 3V, Third ventricle; PVH,
paraventricular nucleus; SON, supraoptic nucleus; AP, anterior
pituitary; IL, intermediate lobe of the pituitary; NL, neural lobe
of the pituitary. Scale bars, 1 mm in (C–E); 100 mm in (A and F);
50 mm in (B).
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reported to be stronglyexpressed in the zona glomerulosa and
the medulla of the human adrenal glands (Baquedano et al.
2007). The fast effects of E2 have previously been described in
primary cultures of bovine adrenal medullary cells with an up
regulation in catecholamine synthesis within 20 min of E2
stimulation (Yanagihara et al. 2006). This suggests a role for
GPR30 in E2 signalling either independently or synergisiti-
cally with extranuclear ERb which is also expressed in cells of
the rat adrenal cortex and medulla (Saunders et al. 1997).
In the kidney, ERa/b are found mainly in the glomeruli
and arterioles of the renal cortex where E2 treatment has been
shown to upregulate angiotensin type II receptors that
regulate sodium and water reabsorption, renal blood ﬂow
and glomerular ﬁltration rate (Baiardi et al. 2005, Oestreicher
et al. 2006). We found high expression of GPR30 mRNA and
protein in the contracting muscle of the pelvis and to a
moderate extent in the medulla. In the renal pelvis, the role of
E2 is presently unclear but there are suggestions that
prolonged E2 administration can encourage renal pelvic
tumour growth (Oberley et al. 1991, Adsay et al. 2000). In
other carcinomas (e.g. breast, endometrial), GPR30
Figure 8 In situ hybridisation of GPR30 mRNA in rodent peripheral
tissues: low-magniﬁcation photograph of a ﬁlm autoradiographic
image of a slide mounted, rat adrenal section hybridised with a
GPR30 probe (A); emulsion dipped section of the mouse adrenal
medulla-hybridisation signal for GPR30 mRNA appears as black
grains on toluidine blue counterstained cells (B); low-magniﬁcation
photograph of a ﬁlm autoradiographic image of a slide mounted,
rat kidney section hybridised with a GPR30 probe (C), with an
absence of signal in the sense control (D); low-magniﬁcation
photograph of a ﬁlm autoradiographic image of a slide mounted,
mouse ovary section hybridised with a GPR30 probe, with
signal localised predominantly in the developing follicles
(E), with an absence of signal in the sense control (F). AM, adrenal
medulla; ZG, zona glomerulosa; RP, renal pelvis; IM, renal
medulla; DF, developing follicle. Scale bars, 1 mm in (A and C–F);
25 mm in (B).
Table 3 An overall comparison of the distribution of GPR30,
oestrogenreceptors(ER) a and b, inthe mouse brain (ResultsforERa
and b are a summary of the mouse brain atlases from Mitra et al.
(2003) and Merchenthaler et al. (2004)
GPR30 ERa ERb
Brain region
Allocortex
Piriform CCC C C
Isocortex
Cingulate CCC K K/C
Motor CCC K K/C
Somatosensory CCC K/CK /C
Hippocampus
Dentate gyrus hilus CCC C K
Subiculum CCC K/CC /CC
Entorhinal cortex CCC K C
Bed nucleus of the
stria terminalis
C CCC CCC
Preoptic area
Medial preoptic
nucleus
CC/CCC CCC CC
Amygdala
Medial nucleus C CCC CCC
Hypothamalmus
Arcuate nucleus CCC CCC C
Paraventricular
nucleus
CCC C CCC
Periventricular
nucleus
CCC CC/CCC K/C
Supraoptic nucleus CCC K C
Ventromedial hypothalamic nucleus
Dorsomedial CCC K/CK
Central CCC CC K
Ventrolateral CCC CCC C/CC
Substantia nigra
Reticular C K CCC
Ventral tegmental
area
KK C C
Periqueductal gray C/CC CC/CCC C
Raphe nuclei
Dorsal raphe C C CCC
Pontine nuclei CCC K C
Anterior tegmental
nucleus
CCC K C
Superior olive
Medioventral
periolivary nucleus
CCC K C
Superior paraolivary
nucleus
CCC K C
Locus coeruleus CCC CC CC
Spinal trigeminal
nucleus
CCC CC K/C
Cerebellum
Purkinje layer CCC K K
Intensity of label: CCC, intense; CC, moderate; C, low; K,a b s .
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et al. 2007). Taken together, it is tempting to speculate that
GPR30 is an alternative oestrogen responsive receptor in the
production and maintenance of renal pelvic tumours.
E2 has been shown to promote cell division and survival of
granulosa cells in developing follicles of the ovary (Adashi
1994). E2 also induces rapid (s) increases in cytosolic calcium
concentration of human granulosa cells in vitro (Younglai et al.
2005). While this could be mediated through the ERb which
has been shown to be highly expressed within the granulosa
cells of developing follicles and corpora lutea of the rat
(Saunders et al. 1997), our results also indicate a role for
GPR30. GPR30 mRNA and protein have been found in
both granulosa and theca cells of the hamster and expression is
sensitive to cyclic changes in FSH and LH (Wang et al. 2007).
It has also been suggested that GPR30 is required for
primordial follicle formation (Wang et al. 2008). These
observations have been appeared to contradict a recent report
which concluded that GPR30 did not mediate E2 responses
in reproductive organs owing to the fertile phenotype of the
GPR30 knockout mice (Otto et al. 2008). In GPR30
knockout animals, the normal phenotypes in E2 responsive
tissues such as the ovary, uterus and mammary gland does not
necessarily preclude the possibility that GPR30 binds E2
in vivo. For example, in the knockout model, ERa and/or
ERb may compensate for the loss of GPR30 especially in
tissues of co-expression where there is potential for receptor
cross-talk (Sirianni et al. 2008). In addition, it is well known
that ERb knockouts remain fertile; it is only the deletion of
ERa which appears to create the infertile phenotype (Walker
& Korach 2004).
While this manuscript was in preparation, four papers
relevant to the possible function of GPR30 in the brain and
adrenal have been published online. Isensee et al. (2009)
analysed the distribution of GPR30 using GPR30-LacZ
reporter mice and found predominant expression in sub
populations of cells in the cortex and the dentate gyrus of the
brain, in the intermediate and anterior lobe of the pituitary
gland and in the adrenal medulla. As shown in Table 1,
GPR30-ir is also highlyexpressed in regions of the cortex and
in the dentate gyrus of the adult mouse brain. Our results also
conﬁrm the presence of GPR30 mRNA in the anterior and
intermediate lobes of the pituitary and the adrenal medulla.
However, in contrast to ourdata that clearly demonstrate both
GPR30 mRNA and protein in the PVH and SON, GPR30
was only identiﬁed in the hypothalamic vasculature and not
neurones in the GPR30-LacZ reporter mice (Isensee et al.
2009). Xu et al. implicate a role for GPR30 in the rat
hypothalamus based on the selective GPR30 agonist G-1
attenuating 5-HT1A signalling within the PVH. They also
conﬁrmed GPR30 expression in OXT neurones (Xu et al.
2009). Another recent study has shown that GPR30 may have
been mediated E2-stimulated release of LHRH in primate
neurones (Noel et al. 2009). In the rodent brain, co-localisa-
tion of GPR30 with LHRH neurones or a possible role of
GPR30 in E2-stimulated LHRH release has yet to be
described. Finally, the expression of GPR30 in the adrenal
medulla of the rat has been conﬁrmed by Dun et al. (2009)
with GPR30 located in tyrosine hydroxylase-positive
chromafﬁn cells, further suggesting a likely role for GPR30
in E2-mediated noradrenaline release from the adrenal glands.
Conclusion
The distribution of GPR30 in the adult mouse brain appears
distinct from ERa and ERb receptors and offers an additional
site for E2 action. The expression of GPR30 in OXTand AVP
neurones in the PVH, SON and in the median eminence, and
its presence in the pituitary gland provides a likely means by
which E2 can modulate fast ‘non-genomic’ effects on these
speciﬁc neuropeptide systems. In the periphery, GPR30 may
be involved in multiple functions including hormone release
and development. Whether E2 initiates responses through
GPR30 alone or in concert with the other E2 receptors (e.g.
in regions of co-expression) has yet to be investigated, but the
cellular distribution of GPR30 in the brain and peripheral
tissues provides a basis for further studies on E2 mediated
signalling.
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